Cargando…
In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study
BACKGROUND: Calculation of individual risk is the cornerstone of effective cardiovascular prevention. arriba is a software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolute effects of pharmacological and lifestyle interventions help the patient...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583804/ https://www.ncbi.nlm.nih.gov/pubmed/23339773 http://dx.doi.org/10.1186/1471-2296-14-13 |
_version_ | 1782475483152121856 |
---|---|
author | Diener, Annette Celemín-Heinrich, Salomé Wegscheider, Karl Kolpatzik, Kai Tomaschko, Katrin Altiner, Attila Donner-Banzhoff, Norbert Haasenritter, Jörg |
author_facet | Diener, Annette Celemín-Heinrich, Salomé Wegscheider, Karl Kolpatzik, Kai Tomaschko, Katrin Altiner, Attila Donner-Banzhoff, Norbert Haasenritter, Jörg |
author_sort | Diener, Annette |
collection | PubMed |
description | BACKGROUND: Calculation of individual risk is the cornerstone of effective cardiovascular prevention. arriba is a software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolute effects of pharmacological and lifestyle interventions help the patient make a well-informed decision. The risk calculation algorithm currently used in arriba is based on the Framingham risk algorithm calibrated to the German setting. The objective of this study is to evaluate and adapt the algorithm for the target population in primary care in Germany. METHODS/DESIGN: arriba-pro will be conducted within the primary care scheme provided by a large health care insurer in Baden-Württemberg, Germany. Patients who are counseled with arriba by their general practitioners (GPs) will be included in the arriba-pro cohort. Exposure data from the consultation with arriba such as demographic data and risk factors will be recorded automatically by the practice software and transferred to the study centre. Information on relevant prescription drugs (effect modifiers) and cardiovascular events (outcomes) will be derived from administrative sources. DISCUSSION: The study is unique in simulating a therapy naïve cohort, matching exactly research and application setting, using a robust administrative data base, and, finally, including patients with known cardiovascular disease who have been excluded from previous studies. TRIAL REGISTRATION: The study is registered with Deutsches Register Klinischer Studien (DRKS00004633). |
format | Online Article Text |
id | pubmed-3583804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35838042013-02-28 In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study Diener, Annette Celemín-Heinrich, Salomé Wegscheider, Karl Kolpatzik, Kai Tomaschko, Katrin Altiner, Attila Donner-Banzhoff, Norbert Haasenritter, Jörg BMC Fam Pract Study Protocol BACKGROUND: Calculation of individual risk is the cornerstone of effective cardiovascular prevention. arriba is a software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolute effects of pharmacological and lifestyle interventions help the patient make a well-informed decision. The risk calculation algorithm currently used in arriba is based on the Framingham risk algorithm calibrated to the German setting. The objective of this study is to evaluate and adapt the algorithm for the target population in primary care in Germany. METHODS/DESIGN: arriba-pro will be conducted within the primary care scheme provided by a large health care insurer in Baden-Württemberg, Germany. Patients who are counseled with arriba by their general practitioners (GPs) will be included in the arriba-pro cohort. Exposure data from the consultation with arriba such as demographic data and risk factors will be recorded automatically by the practice software and transferred to the study centre. Information on relevant prescription drugs (effect modifiers) and cardiovascular events (outcomes) will be derived from administrative sources. DISCUSSION: The study is unique in simulating a therapy naïve cohort, matching exactly research and application setting, using a robust administrative data base, and, finally, including patients with known cardiovascular disease who have been excluded from previous studies. TRIAL REGISTRATION: The study is registered with Deutsches Register Klinischer Studien (DRKS00004633). BioMed Central 2013-01-22 /pmc/articles/PMC3583804/ /pubmed/23339773 http://dx.doi.org/10.1186/1471-2296-14-13 Text en Copyright ©2013 Diener et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol Diener, Annette Celemín-Heinrich, Salomé Wegscheider, Karl Kolpatzik, Kai Tomaschko, Katrin Altiner, Attila Donner-Banzhoff, Norbert Haasenritter, Jörg In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
title | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
title_full | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
title_fullStr | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
title_full_unstemmed | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
title_short | In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
title_sort | in-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583804/ https://www.ncbi.nlm.nih.gov/pubmed/23339773 http://dx.doi.org/10.1186/1471-2296-14-13 |
work_keys_str_mv | AT dienerannette invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT celeminheinrichsalome invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT wegscheiderkarl invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT kolpatzikkai invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT tomaschkokatrin invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT altinerattila invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT donnerbanzhoffnorbert invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy AT haasenritterjorg invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy |